109155 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone
MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#302Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
#303Methods and compositions for selecting siRNA of improved functionality
#304Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#305Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#306C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
#307Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
#308UNA single stranded oligomers for therapeutics
#309LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
#310Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#311Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#312Method of nonspecific target capture of nucleic acids
#313Modulation of HSP47 expression
#314Hydrophobically modified antisense oligonucleotides comprising a ketal group
#315Compounds and methods for trans-membrane delivery of molecules
#316Compositions and methods for modulating apolipoprotein (a) expression
#317Compositions and methods for modulating apolipoprotein C-III expression
#318Compositions and methods
#319Compositions and methods for modulating HBV expression
#320Structure and use of 5′ phosphate oligonucleotides
#321Compositions and methods for modulating Tau expression
#3222-fluoro-modified RNAs as immunostimulators
#323Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#324PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS (PMOS) AND THEIR USE IN SUPPRESSION OF MUTANT HUNTINGTIN EXPRESSION AND ATTENUATION OF NEUROTOXICITY
#325METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS
#326Selective antisense compounds and uses thereof
#327Modified oligonucleotides for telomerase inhibition
#328Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
#329Compounds and methods for modulating gene expression
#330Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#331Modified oligonucleotides for telomerase inhibition
#332Modified oligonucleotides for telomerase inhibition
#333COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS
#334Compositions and their uses directed to huntingtin
#335In vivo gene silencing by chemically modified and stable siRNA
#336Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#337Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#338ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY
#339UNA oligomers targeting micro-RNA for therapeutics
#340UNA duplex oligomers for therapeutics
#341Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#342Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#343Chiral control
#344Modified RNAi agents
#345Oligomeric compounds and methods
#346COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION
#347Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#348ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY
#349Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#350Boronic acid conjugates of oligonucleotide analogues
#351Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#352Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#353Induced exon inclusion in spinal muscle atrophy
#354Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#355Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#356Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#357TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF
#358Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#359Modified oligonucleotides for telomerase inhibition
#360Inhibitors of FAM3B gene, inhibitor compositions, inhibiting methods and applications of inhibitors in preparing pharmaceuticals
#361Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#362Organic compositions to treat Beta-ENaC-related diseases
#363Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#364Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#365Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#366Structure and use of 5′ phosphate oligonucleotides
#367Method of inhibiting miR-33 using a modified oligonucleotide
#368COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY
#369COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR
#370COMPOSITIONS COMPRISING IMMUNOSTIMULATORY NUCLEIC ACIDS AND RELATED METHODS
#371TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE
#372Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#373Oligonucleotide end caps
#374MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
#375Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
#376Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
#377Organic compositions to treat Beta-ENaC-related diseases
#378Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#379Organic compositions to treat beta-ENaC-related diseases
#380Organic compositions to treat Beta-ENaC-related diseases
#381Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#382Method for inhibiting the activity of mir-155
#383Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#384Oligomeric compounds and methods
#385Modulation of exon recognition in pre-mRNA by interfering RNA structure
#386Compositions and their uses directed to huntingtin
#387Means and methods for counteracting muscle disorders
#388METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#389Organic compositions to treat beta-ENaC-related diseases
#390RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis
#391Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#392RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA
#393Modulation of HSP47 expression
#394Antisense composition and method for treating muscle atrophy
#395Compounds and methods for modulating expression of SGLT2
#396Method for inhibiting the activity of mir-155
#397RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
#398Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#399DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
#400DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER ASSOCIATED CHROMOSOMAL FEATURES
#401STRUCTURE AND USE OF 5'PHOSPHATE OLIGONUCLEOTIDES
#402CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
#403COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#404Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
#405COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF CRP
#406COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2
#407Compounds and methods for modulating expression of PTP1B
#408Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#409Compounds and methods for modulating expression of GCCR
#410Compounds and methods for modulating expression ApoB
#411Compounds and methods for modulating expression of GCGR
#412Compounds and methods for modulating expression of PCSK9
#413Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#414COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DGAT2
#415Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#416Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#417Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
#418MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
#419ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY
#420Antisense antiviral compounds and methods for treating a filovirus infection
#421Antisense antiviral compounds and methods for treating a filovirus infection
#422Antisense antiviral compounds and methods for treating a filovirus infection
#423Combination motif immune stimulatory oligonucleotides with improved activity
#424Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#425RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA
#426RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
#427Methods of nonspecific target capture of nucleic acids
#428Oligomeric compounds for the modulation ras expression
#429Nucleic Acids For Apoptosis Of Cancer Cells
#430Compositions and their uses directed to huntingtin
#431Short antisense compounds with gapmer configuration
#432COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#433Human RNase H1 oligonucleotide compositions thereof
#434Antisense composition and method for treating muscle atrophy
#435Anti-apoptotically active apatamers
#436Antisense antiviral compounds and methods for treating a filovirus infection
#437Oligomeric compounds and compositions for use in modulation of pri-mirnas
#438Oligomeric compounds for use in gene modulation
#439Antisense antiviral compounds and methods for treating a filovirus infection
#440Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#441Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
#442Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#443Oligoribonucleotide derivatives for specific inhibition of gene expression
#444Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#445C-class oligonucleotide analogs with enhanced immunostimulatory potency
#446Chemically modified double stranded nucleic acid molecules
#447Modified oligonucleotides for telomerase inhibition
#448In vivo gene silencing by chemically modified and stable siRNA
#449Conjugated antisense compounds and their use
#450Modified RNA agents with reduced off-target effect